NATIONAL MASTERCLASS
IN RENAL CELL CARCINOMA – 3^rd edition

From sculpting strategy to thoughtful treatment

16 & 17 January 2026

12:30 - 18:30 (Day 1) & 08:30 - 13:00 (Day 2)

Dolce La Hulpe Brussels

Preliminary program

Day 1

Day 2

13:30 – 13:45

SESSION 1 - Moderators: Prof. Gennigens & Dr. Gizzi

Biomarkers

The evolving role of biomarkers: from concept to clinical impact

Prof. Rottey

Adjuvant therapy

The pro’s and con’s of adjuvant therapy

Prof. Gennigens & Prof. Beuselinck

Local therapy in the locally advanced/metastatic setting

Debulking surgery in metastatic RCC: benefits and limitations
Optimizing radiation therapy in RCC: Expert insights and best practices

Prof. Van Praet
Prof. Berghen

15:30 – 16:00

BREAK

16:00 – 18:10

SESSION 2 - Moderators: Prof. Martinez & Prof. Seront

1^st Line treatments

Current landscape of first-line treatment in RCC
The critical role of chronobiology in modern medicine
The debate on IO treatment duration: current evidence and future directions
Non-clear cell RCC - understanding the new classification and guiding treatment decisions

Dr. Carril
Prof. Beuselinck
Dr. Decruyenaere
Prof. Verbiest

Current 2^nd line and beyond

2L and beyond: treatment strategies post IO/IO & IO/TKI

Dr. Gizzi

Real cases, real strategies

Masterclass in action: interactive case discussions

Prof. Martinez
Prof. Seront
Prof. Gennigens

18:10 – 18:30

CLOSING/CONCLUSIONS

DINNER

08:30 – 10:30

SESSION 3 - Moderators: Prof. Martinez & Prof. Rottey

Managing complex cases in specific patient populations

How to manage therapy after a renal transplant
Therapeutic considerations in patients with autoimmune disease

Prof. Aspeslagh
Prof. Aspeslagh

How to handle challenging IO toxicities?

BITOX
Immune-related neurological toxicities
Immunotherapy-Induced hypophysitis: diagnosis, challenges, and therapeutic strategies

Prof. Aspeslagh
Dr. Van Wylick
Dr. Martens

How to handle challenging TKI toxicities?

Intensification or de-escalation approach in 1st line ?

Prof. Seront

10:30 – 11:00

BREAK

11:00 – 12:45

SESSION 4 - Moderators: Prof. Beuselinck & Prof. Gennigens

What’s in the pipeline?

Upcoming therapeutic advances
The role of nuclear medicine in RCC

Prof. Rottey
Prof. Withofs

Belgian research updates: fellow-led presentations

Optimal treatment of brain metastases in RCC
Role of eosinophils in clear-cell renal cell carcinoma
Medication-related osteonecrosis of the jaw
TKI-related toxicity marker as therapy response predictor in metastatic RCC
HBOC germline mutations and efficacy of immune checkpoint inhibitors (BEL-RCC2 study)

Dr. Roodhooft
Dr. Gilon
Dr. Mammone
Dr. Vermassen
Dr. Vrijders

12:45 – 13:00